Sarepta eyes multiple sclerosis gene therapy, page-15

There's a few discrepancies there - but sure give it to 'em pumper lol

Plenty of upside for ANP should trials prove successful but they're not in the same position Sarepta (AVI) was at the time of their steep ascent.

Sarepta's trial or (AVI at the time) was a Phase IIb trial (the one ANP hopes to progress to should this be successful and what they are trying to get approval for through the EMA) the Primary Efficacy Endpoint of increased Dystrophin and Primary Clinical Outcome was a 6 minute walk test - their safety and tolerability was shown long before.

Sarepta (AVI) also had $30M in cash and whilst running at loss after costs of R&D still had 10x cash of what ANP presently stands on - probably only 3x if all options are converted. They also had revenue of $30/$40M a year based on the infectious disease program through the US Government.